Cassava Sciences Inc (OQ:SAVA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 6801 N CAPITAL OF TEXAS HIGHWAY
BUILDING 1; SUITE 300
AUSTIN TX 78731
Tel: N/A
Website: https://www.cassavasciences.com
IR: See website
<
Key People
Remi Barbier
Chairman of the Board, President, Chief Executive Officer
Eric J. Schoen
Chief Financial Officer
R. Christopher Cook
Senior Vice President, General Counsel
James W. Kupiec
Chief Medical Officer
   
Business Overview
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.
Financial Overview
For the fiscal year ended 31 December 2023, Cassava Sciences Inc revenues was not reported. Net loss increased 28% to $97.2M. Higher net loss reflects Other General & Admin increase of 21% to $14M (expense), Stock-Based Compensation Expense increase from $435K to $2.5M (expense), Other income, net decrease of 9% to $907K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.90 to -$2.32.
Employees: 29 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $761.52M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$104.43M as of Dec 31, 2023
Net annual income (TTM): -$97.22M as of Dec 31, 2023
Free cash flow (TTM): -$82.44M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 43,245,758 as of Mar 19, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.